全文获取类型
收费全文 | 8221篇 |
免费 | 712篇 |
国内免费 | 3篇 |
出版年
2023年 | 29篇 |
2021年 | 105篇 |
2020年 | 69篇 |
2019年 | 75篇 |
2018年 | 112篇 |
2017年 | 103篇 |
2016年 | 181篇 |
2015年 | 320篇 |
2014年 | 367篇 |
2013年 | 444篇 |
2012年 | 565篇 |
2011年 | 564篇 |
2010年 | 416篇 |
2009年 | 356篇 |
2008年 | 501篇 |
2007年 | 504篇 |
2006年 | 460篇 |
2005年 | 483篇 |
2004年 | 506篇 |
2003年 | 445篇 |
2002年 | 476篇 |
2001年 | 71篇 |
2000年 | 57篇 |
1999年 | 118篇 |
1998年 | 140篇 |
1997年 | 56篇 |
1996年 | 67篇 |
1995年 | 64篇 |
1994年 | 73篇 |
1993年 | 87篇 |
1992年 | 83篇 |
1991年 | 63篇 |
1990年 | 76篇 |
1989年 | 49篇 |
1988年 | 62篇 |
1987年 | 60篇 |
1986年 | 57篇 |
1985年 | 50篇 |
1984年 | 69篇 |
1983年 | 48篇 |
1982年 | 65篇 |
1981年 | 73篇 |
1980年 | 46篇 |
1979年 | 46篇 |
1978年 | 41篇 |
1977年 | 43篇 |
1976年 | 36篇 |
1975年 | 25篇 |
1974年 | 27篇 |
1973年 | 22篇 |
排序方式: 共有8936条查询结果,搜索用时 125 毫秒
991.
Immunological characteristics correlating with clinical response to immunotherapy in patients with advanced metastatic melanoma 总被引:1,自引:0,他引:1
Marshall JA Forster TH Purdie DM Lanagan CM O'Connor LE O'Rourke MG Johnson MK See JL Ellem KA Martinez NR López JA Schmidt CW 《Immunology and cell biology》2006,84(3):295-302
Current treatment options for advanced metastatic melanoma are limited to experimental regimen that provide poor survival outcomes. Immunotherapy is a promising alternative and we recently reported a clinical trial in which 6 out of 19 patients enrolled had objective clinical responses to a fully autologous melanoma/dendritic cell vaccine. The mechanism of the vaccine is not well understood, but we hypothesized that general immunocompetence may be a determinant of clinical response. We therefore examined the immune status of an expanded series of 21 patients who displayed varying clinical responses to the melanoma/dendritic cell vaccine. Immunocompetence was assessed using in vitro assays of lymphocyte function: survival, proliferation and cytokine responses to mitogen stimulation as well as T-cell receptor zeta expression and lymphocyte subset analysis. Although lymphocytes from patients mostly performed comparably to age-matched and sex-matched controls, in some assays we identified significant differences between complete clinical responders and other patients, both before and following vaccination. Surprisingly, before vaccination, only lymphocytes from clinical responder patients showed impaired in vitro survival. Following vaccination, T lymphocyte survival improved and cells recovered their ability to produce the Th1-associated cytokines TNF and IFN-gamma in response to anti-CD3 stimulation in vitro. No increase in Th1 cytokine production was observed in lymphocytes from patients who experienced partial clinical responses or progressive disease. We conclude that, before vaccination, patients who go on to have complete responses have immune characteristics suggestive of high cell turnover and low Th1-associated cytokine production, and that these can be reversed with vaccination. These results have potential implications for future immunotherapeutic strategies. 相似文献
992.
DiDonato M Krishna SS Schwarzenbacher R McMullan D Jaroszewski L Miller MD Abdubek P Agarwalla S Ambing E Axelrod H Biorac T Chiu HJ Deacon AM Elsliger MA Feuerhelm J Godzik A Grittini C Grzechnik SK Hale J Hampton E Haugen J Hornsby M Klock HE Knuth MW Koesema E Kreusch A Kuhn P Lesley SA Moy K Nigoghossian E Okach L Paulsen J Quijano K Reyes R Rife C Spraggon G Stevens RC van den Bedem H Velasquez J White A Wolf G Xu Q Hodgson KO Wooley J Wilson IA 《Proteins》2006,63(1):256-260
993.
Mathews II Krishna SS Schwarzenbacher R McMullan D Jaroszewski L Miller MD Abdubek P Agarwalla S Ambing E Axelrod HL Canaves JM Carlton D Chiu HJ Clayton T DiDonato M Duan L Elsliger MA Grzechnik SK Hale J Hampton E Haugen J Jin KK Klock HE Koesema E Kovarik JS Kreusch A Kuhn P Levin I Morse AT Nigoghossian E Okach L Oommachen S Paulsen J Quijano K Reyes R Rife CL Spraggon G Stevens RC van den Bedem H White A Wolf G Xu Q Hodgson KO Wooley J Deacon AM Godzik A Lesley SA Wilson IA 《Proteins》2006,65(1):249-254
994.
Xu Q Krishna SS McMullan D Schwarzenbacher R Miller MD Abdubek P Agarwalla S Ambing E Astakhova T Axelrod HL Canaves JM Carlton D Chiu HJ Clayton T DiDonato M Duan L Elsliger MA Feuerhelm J Grzechnik SK Hale J Hampton E Han GW Haugen J Jaroszewski L Jin KK Klock HE Knuth MW Koesema E Kreusch A Kuhn P Morse AT Nigoghossian E Okach L Oommachen S Paulsen J Quijano K Reyes R Rife CL Spraggon G Stevens RC van den Bedem H White A Wolf G Hodgson KO Wooley J Deacon AM Godzik A Lesley SA Wilson IA 《Proteins》2006,65(3):777-782
995.
DiDonato M Krishna SS Schwarzenbacher R McMullan D Agarwalla S Brittain SM Miller MD Abdubek P Ambing E Axelrod HL Canaves JM Chiu HJ Deacon AM Duan L Elsliger MA Godzik A Grzechnik SK Hale J Hampton E Haugen J Jaroszewski L Jin KK Klock HE Knuth MW Koesema E Kreusch A Kuhn P Lesley SA Levin I Morse AT Nigoghossian E Okach L Oommachen S Paulsen J Quijano K Reyes R Rife CL Spraggon G Stevens RC van den Bedem H White A Wolf G Xu Q Hodgson KO Wooley J Wilson IA 《Proteins》2006,65(3):771-776
996.
997.
998.
999.
Modification of proteins by post-translational covalent attachment of a single, or chain, of ubiquitin molecules serves as
a signaling mechanism for a number of regulatory functions in eukaryotic cells. For example, proteins tagged with lysine-63
linked polyubiquitin chains are involved in error-free DNA repair. The catalysis of lysine-63 linked polyubiquitin chains
involves the sequential activity of three enzymes (E1, E2, and E3) that ultimately transfer a ubiquitin thiolester intermediate
to a protein target. The E2 responsible for catalysis of lysine-63 linked polyubiquitination is a protein heterodimer consisting
of a canonical E2 known as Ubc13, and an E2-like protein, or ubiquitin conjugating enzyme variant (UEV), known as Mms2. We
have determined the solution structure of the complex formed by human Mms2 and ubiquitin using high resolution, solution state
nuclear magnetic resonance (NMR) spectroscopy. The structure of the Mms2–Ub complex provides important insights into the molecular
basis underlying the catalysis of lysine-63 linked polyubiquitin chains. 相似文献
1000.
Van De Wiele CJ Joachims ML Fesler AM Vaughn JG Blackburn MR McGee ST Thompson LF 《Journal of immunology (Baltimore, Md. : 1950)》2006,176(10):5925-5933
Murine fetal thymic organ culture (FTOC) was used to investigate the mechanism by which a lack of adenosine deaminase (ADA) leads to a failure of T cell production in the thymus. We previously showed that T cell development was inhibited beginning at the CD4(-)CD8(-)CD25(+)CD44(low) stage in ADA-deficient FTOC initiated at day 15 of gestation when essentially all thymocytes are CD4(-)CD8(-). In the present study, we asked whether thymocytes at later stages of differentiation would also be sensitive to ADA inhibition by initiating FTOC when substantial numbers of CD4(+)CD8(+) thymocytes were already present. dATP was highly elevated in ADA-deficient cultures, and the recovery of alphabeta TCR(+) thymocytes was inhibited by 94%, indicating that the later stages of thymocyte differentiation are also dependent upon ADA. ADA-deficient cultures were partially rescued by the pan-caspase inhibitor carbobenzoxy-Val-Ala-Asp-fluoromethyl ketone or by the use of apoptotic protease-activating factor-1-deficient mice. Rescue was even more dramatic, with 60- to >200-fold increases in the numbers of CD4(+)CD8(+) cells, when FTOC were performed with an inhibitor of adenosine kinase, the major thymic deoxyadenosine phosphorylating enzyme, or with bcl-2 transgenic mice. dATP levels were normalized by treatment with either carbobenzoxy-Val-Ala-Asp-fluoromethyl ketone or an adenosine kinase inhibitor, but not in cultures with fetal thymuses from bcl-2 transgenic mice. These data suggest that ADA deficiency leads to the induction of mitochondria-dependent apoptosis as a consequence of the accumulation of dATP derived from thymocytes failing the positive/negative selection checkpoint. 相似文献